Healthcare / Medical Care FacilitiesNasdaqCM
$6.12
-0.19 (-3.01%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-35.5M · quality 79.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
52/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$530M
P/E
12.2x
↓EV/EBITDA
N/A
•ROE
14.8%
↑Gross Margin
20.9%
↓Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2019–2025 · 6 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-30.4%
FCF / Net income
-1.45x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $197.1M · net income $41.3M · FCF $-59.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | $197.1M | $197.1M | $146.8M | $225.2M | $146.1M | — | — | — |
| Net Income | $41.3M | $41.3M | $-27.3M | $-56.1M | $-27.3M | — | $-20.5M | $2.3M |
| EBITDA | $-14.2M | $-14.2M | $-16.6M | $-61.0M | $-47.8M | — | — | — |
| EPS | 0.50 | 0.50 | -0.34 | -0.76 | -0.38 | — | — | — |
| Gross Margin | 20.9% | 20.9% | 20.2% | 18.7% | 15.2% | — | — | — |
| Operating Margin | -11.3% | -11.3% | -15.3% | -30.3% | -36.6% | — | — | — |
| Net Margin | 21.0% | 21.0% | -18.6% | -24.9% | -18.7% | — | — | — |
| Balance Sheet | ||||||||
| Debt/Equity | 0.01 | 0.01 | 0.01 | 0.10 | 0.07 | — | — | — |
| Current Ratio | 5.93 | 5.93 | — | — | — | — | — | — |
| Cash Flow | ||||||||
| Free Cash Flow | $-59.9M | $-59.9M | $-35.5M | $-34.5M | $-37.9M | — | — | — |
| Returns | ||||||||
| ROE | 14.8% | 14.8% | -12.3% | -23.9% | -9.9% | — | -410.4% | 46.6% |
| Valuation | ||||||||
| P/E | 12.24 | 12.24 | — | — | — | — | — | — |
| P/B | 1.80 | 1.80 | 1.71 | 0.98 | 0.90 | — | — | — |
| Growth & Yield | ||||||||
| Revenue Growth | 34.3% | 34.3% | -34.8% | 54.1% | — | — | — | — |
| EPS Growth | 245.4% | 245.4% | 54.8% | -99.8% | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
2.8%
EPS terminal req.
$0.54
Spread vs growth
242.6%
5Y implied EPS CAGR
5.6%
EPS terminal req.
$0.66
Spread vs growth
239.8%
10Y implied EPS CAGR
7.8%
EPS terminal req.
$1.06
Spread vs growth
237.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+75.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.34 → 0.50
Residual
+75.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.